Targeted Protein Degradation - New Modalities and Design Technologies
DATE
December 5, 2024
TIME
8:00 a.m. PST, 11:00 a.m. EST, 16:00 GMT, 17:00 CET - Duration: 60 Minutes
Overview
Hear from two leading experts in drug discovery as they explore innovative approaches to targeting previously undruggable proteins. Dr. Bernhard Fasching from Monte Rosa Therapeutics will present their QuEEN™ platform, which combines AI-powered chemistry and high-throughput screening to discover molecular glue degraders (MGDs). Dr. Benedict Cross from PhoreMost will share insights on their unique approach using engineered mini-proteins and phenotypic screening to enable small molecule drug discovery, particularly focusing on the Ubiquitin Proteasome System (UPS).
Key Learning Objectives:
- Understand why Targeted Protein Degradation (TPD) is crucial for modern drug discovery, particularly for the 85% of proteins considered undruggable by conventional small molecule inhibitors.
- Explore the mechanisms and various types of Molecular Glue Degraders (MGDs), including both serendipitously discovered and rationally designed examples.
- Learn about new technological platforms for systematic MGD discovery, including Monte Rosa's AI-powered QuEEN™ toolbox and PhoreMost's mini-protein approach for targeting challenging proteins.
Who Should Attend:
- Biologists
- Biotech lab managers
- Biotech executives
Brought to you by:
Speakers
Benedict Cross, PhDCTO
PhoreMost Therapeutics
Bernhard Fasching, PhDVP Chemistry
Monte Rosa Therapeutics
Melissa O'MearaForensic Science Consultant
C&EN Media Group
Registration
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.
© 2024 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy